The psychological reactions of patients in response to cancer have been the object of psycho-oncology research since the first studies carried out by Arthur M. Sutherland in the middle of the last century.1 Subsequent better designed investigations were carried out in many parts of the world using standardized psychiatric interviews according to the Diagnostic Statistical Manual for Mental Disorders (DSM) of the American Psychiatric Association and the International Classification of Diseases (ICD) of the World Health Organization. Meta-analyses of these studies are now available 2 and indicate that approximately 30% to 40% of patients with cancer meet the criteria for a psychiatric diagnosis-especially depressive disorders-that have extremely negative consequences for the patients and their families (eg, impairment of quality of life, longer rehabilitation processes, risk of suicide, reduction in adherence to treatment).It is clear that having a system to codify the psychiatric disorders observable in oncology, including depression, is extremely important for a whole-person-centered approach that includes psychosocial aspects as mandatory targets. However, the psycho-oncology literature has demonstrated that many other psychosocial dimensions not detectable with classical psychiatric nosology (ie, ICD and DSM) are extremely common and have a remarkable role in negatively influencing a patient's quality of life. 3,4 Demoralization is one of the most important among the aforesaid constructs. It can be clinically separated from depressive disorders, has a high prevalence in medical disorders, and thus needs to be carefully examined, correctly measured, and treated. There have been several recent reports about the importance of demoralization, particularly in the settings of cancer and palliative care. [5][6][7] In this issue of Cancer, Robinson et al 8,9 explore the application of a new, refined, 16-item, self-report measure of demoralization (Demoralization Scale-II [DS-II]) in patients with cancer or other progressive diseases who were receiving palliative care. The analyses by Robinson and colleagues highlight the need for clinicians to consider demoralization as a significant clinical entity to be taken seriously into account in cancer settings.
Demoralization Syndrome and its AssessmentThe concept of demoralization